• Corpus ID: 30633553

The efficacy of combination of chemotherapy and cytokine-induced killer cells therapy for soft tissue cancer : a meta-analysis

@inproceedings{Chen2017TheEO,
  title={The efficacy of combination of chemotherapy and cytokine-induced killer cells therapy for soft tissue cancer : a meta-analysis},
  author={Qiaoling Chen and Yiguang Bai and Dongqin Xiao and Kang Liu and Xiaocong Xiang and Gang Feng},
  year={2017}
}
Purpose: To assess the efficacy of combined therapy of chemotherapy and cytokine-induced killer (CIK) cells on treatment of multiple types of soft tissue tumors with overall survival (OS). Methods: Pooling all data together, we assessed the effect of combination of chemotherapy and CIK cells therapy on 1-year, 2-year, 3-year and 5-year OS. Similar subgroup was also performed on colorectal and gastric tumors. The overall odds ratio (OR) and its corresponding 95% confidence interval (95% CI) for… 

Figures and Tables from this paper

References

SHOWING 1-10 OF 28 REFERENCES
Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer.
TLDR
It was concluded that chemotherapy plus CIK cells has potential benefits compared to chemotherapy alone in patients suffering from advanced NSCLC and autologous CIK cell transfusion has no obvious side-effects.
Combination of chemotherapy and immunotherapy for colon cancer in China: a meta-analysis.
TLDR
The combination of DC-CIK immunotherapy and chemotherapy was superior in prolonging the survival time and enhancing immunological responses.
Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: a retrospective study of 165 patients.
TLDR
It is suggested that immunotherapy with CIK cells may serve as an adjuvant treatment to prolong the survival of patients with stage II-III gastric carcinoma.
Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer
TLDR
Adjuvant immunotherapy with CIK cells prolongs DFS in patients with locally advanced gastric cancer and significantly improves OS in patientsWith intestinal-type tumors could be selected as an important indication for CIK-cell therapy.
The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients
TLDR
Postoperative immunotherapy with CIK cell transfusion with CIK cell infusion may be an effective adjuvant treatment for improving the outcomes of HCC patients; >8 cycles of CIKcell transfusion may ensure that patients derive maximal benefits.
Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma.
Effects of cytokine-induced killer cell treatment in colorectal cancer patients: a retrospective study.
Efficacy of Erlotinib Plus Dendritic Cells and Cytokine-induced Killer Cells in Maintenance Therapy of Advanced Non–Small Cell Lung Cancer
TLDR
DC/CIK plus erlotinib was well tolerated with a manageable safety profile and there was no statistically significant difference in overall survival between DC/Cik plus erLotinib and erlot inib as maintenance therapy.
Effects of cytokine-induced killer cell treatment combined with FOLFOX4 on the recurrence and survival rates for gastric cancer following surgery
TLDR
It is concluded that FOL FOX4 combined with CIK cell treatment has significant benefits for patients suffering from gastric cancer, compared with FOLFOX4 treatment alone.
Impact of cellular immune function on prognosis of lung cancer patients after cytokine-induced killer cell therapy.
TLDR
The immune function of lung cancer patients was improved by CIK cell therapy, associated with an increase in the OS rate and extension of the time to recurrence and/or metastasis.
...
...